The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.

Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has not been limited to just a handful of companies either, with most S&P 500 sectors contributing to earnings growth during the current reporting season.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new invest

Why treatments from Alnylam, Merck, AbbVie and Roche stumbled in the last quarter.

Investors need to pay close attention to ALNY stock based on the movements in the options market lately.

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Starbucks upgraded, eBay downgraded: Wall Street's top analyst calls

The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.

Alnylam stock plunges after Q2 earnings and revenue miss estimates, while a cut to 2026 product sales guidance overshadows record quarterly Amvuttra sales.

The Morning Bull - US Market Morning Update Friday, Jul, 31 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.3% and Nasdaq-100 futures ahead roughly 0.5%. The focus is on the June US PCE price index, which is expected to dip 0.1% month on month, while the core reading is seen up 0.2%. That combination suggests the cost of living may be easing slowly but still sits above the Federal Reserve's 2% goal. At the same time, second quarter US GDP is...

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Alnylam's Q2 2026 revenue surged 74% to $1.2 billion, driven by Amvuttra's record quarter, though the company lowered its full-year guidance due to a normalization of second-line demand.

US equity indexes ended higher Thursday after Microsoft (MSFT) posted AI-backed gains and semiconduc

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported second-quarter 2026 global net product revenue of approximately $1.2 billion, up 74% from a year earlier, driven by continued uptake of AMVUTTRA for transthyretin amyloidosis with cardiomyopathy, or ATTR-CM. Chief Executive Officer Yvonne Greenstreet s

The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Alnylam (ALNY) delivered earnings and revenue surprises of -10.24% and -2.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) is back in focus after its presentations at the Alzheimer’s Association International Conference in London, where the company outlined fresh clinical progress in RNAi therapies targeting Alzheimer’s disease. See our latest analysis for Alnylam Pharmaceuticals. The Alzheimer’s presentations and progress with mivelsiran and ALN-5288 come after a mixed period for Alnylam Pharmaceuticals’ stock, with the share price rising 7.48% over the past week but down 28.29%...

In July 2026, Alnylam Pharmaceuticals presented new clinical data and study designs for its Alzheimer’s disease RNAi candidates mivelsiran and ALN-5288 at the Alzheimer’s Association International Conference in London, including long-term safety findings and robust cerebrospinal fluid biomarker reductions in early-onset Alzheimer’s disease. These updates, combined with completion of enrollment in the cAPPricorn-1 study in cerebral amyloid angiopathy and initiation of the APPlauDS trial in...

Beyond analysts' top-and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

2026 has marked a significant turning point in biotech capital markets, not just a small comeback. Venture funding for biotech startups reached $9.1 billion in the first half of the year, the highest first-half total since 2022, while 13 biotech IPOs raised a combined $4.5 billion, with a median haul of nearly $302 million per […]

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Growth Stocks With Highest Upside Potential. On July 10, 2026, Morgan Stanley raised the firm’s price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $400 from $370 and kept an Equal Weight rating on the shares. On July 9, Raymond James raised the firm’s price target […]

Alnylam Pharmaceuticals' (ALNY) Q2 financial results will be important in determining where 2026 rev

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.